Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a precision cardiovascular medicine company, has engaged IBN to support its corporate communications strategy. The company focuses on developing blood-based solutions for preventing and detecting cardiovascular disease by leveraging epigenetics, genetics, and artificial intelligence.
The company commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to generate patient-specific insights. Its product portfolio includes Epi+Gen CHD(TM), a prescription-only test for assessing three-year coronary heart disease risk, PrecisionCHD(TM) for detection and management, HeartRisk(TM) for population-level intelligence, and CardioInnovate360(TM) to support cardiovascular therapy development.
Cardio Diagnostics aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise through its proprietary AI-driven Integrated Genetic-Epigenetic Engine, which serves as its core technology. The company's engagement with IBN, part of the Dynamic Brand Portfolio, provides access to specialized communications services in the biotechnology and biomedical sectors.
IBN offers corporate communications solutions through its newsroom platform, which provides the latest updates relating to CDIO. The platform delivers wire solutions, article syndication to thousands of outlets, enhanced press release distribution, and social media distribution to millions of followers.
This partnership occurs as Cardio Diagnostics seeks to establish itself as a leading medical technology company in cardiovascular disease management. The company's approach combines epigenetic and genetic data with artificial intelligence to create more accurate risk assessments and treatment pathways for cardiovascular conditions, which remain a leading cause of mortality worldwide.
The engagement with IBN's specialized communications platform may enhance Cardio Diagnostics' visibility among investors, healthcare professionals, and the broader medical community. This increased visibility could support the adoption of the company's AI-powered diagnostic tools in clinical settings, potentially improving early detection and personalized management of cardiovascular disease.
For business and technology leaders, this development highlights the growing intersection of artificial intelligence, precision medicine, and corporate communications in the healthcare technology sector. The partnership demonstrates how specialized communications strategies can support companies developing complex AI-driven medical solutions as they navigate regulatory pathways and market adoption challenges.
